liothyronine


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to liothyronine: Cytomel, Liothyronine sodium

liothyronine

 [li″o-thi´ro-nēn]
a synthetic pharmaceutical preparation of the levorotatory isomer of triiodothyronine; used for replacement therapy in hypothyroidism and for the prophylaxis and treatment of goiter and of thyroid cancer; administered orally or intravenously as the sodium salt.

liothyronine

(lye-oh-thye-roe-neen) ,

Cytomel

(trade name),

l-triiodothyronine

(trade name),

T3

(trade name),

Triostat

(trade name)

Classification

Therapeutic: hormones
Pharmacologic: thyroid preparations
Pregnancy Category: A

Indications

Thyroid supplementation in hypothyroidism.Treatment or suppression of euthyroid goiters.Diagnostic agent for suppression tests to differentiate mild hyperthyroidism from thyroid gland autonomy.Treatment of myxedema coma (IV formulation).

Action

Replacement of or supplementation to endogenous thyroid hormones.
Principal effect is increasing metabolic rate of body tissues:
  • Promote gluconeogenesis,
  • Increase utilization and mobilization of glycogen stores,
  • Stimulate protein synthesis,
  • Promote cell growth and differentiation,
  • Aid in the development of the brain and CNS.

Therapeutic effects

Replacement in hypothyroidism to restore normal hormonal balance.

Pharmacokinetics

Absorption: Liothyronine is well absorbed.
Distribution: Distributed into most body tissues. Thyroid hormones do not readily cross the placenta; minimal amounts enter breast milk.
Metabolism and Excretion: Metabolized by the liver and other tissues. Thyroid hormone undergoes enterohepatic recirculation and is excreted in the feces via the bile.
Half-life: 1–2 days.

Time/action profile

ROUTEONSETPEAKDURATION
Liothyronine POunknown24–72 hr72 hr
Liothyronine IVunknownunknownunknown

Contraindications/Precautions

Contraindicated in: Hypersensitivity; Recent MI; Hyperthyroidism.
Use Cautiously in: Cardiovascular disease (initiate therapy with lower doses); Severe renal insufficiency; Uncorrected adrenocortical disorders; Geriatric: ↑sensitivity to thyroid hormones; initial dose should be ↓.

Adverse Reactions/Side Effects

Usually only seen when excessive doses cause iatrogenic hyperthyroidism

Central nervous system

  • insomnia
  • irritability
  • headache

Cardiovascular

  • arrhythmias
  • tachycardia
  • angina pectoris

Gastrointestinal

  • abdominal cramps
  • diarrhea
  • vomiting

Dermatologic

  • hyperhidrosis

Endocrinologic

  • hyperthyroidism
  • menstrual irregularities

Metabolic

  • weight loss
  • heat intolerance

Musculoskeletal

  • accelerated bone maturation in children

Interactions

Drug-Drug interaction

Bile acid sequestrants ↓ absorption of orally administered thyroid preparations.Alters the effectiveness of warfarin (INR will ↑ with thyroid hormone supplementation).May ↑ requirement for insulin or oral hypoglycemic agents in diabetics.Concurrent estrogen therapy may ↑ thyroid replacement requirements.↑ cardiovascular effects with adrenergics (sympathomimetics).

Route/Dosage

Oral (Adults) Mild hypothyroidism—25 mcg once daily; may ↑ by 12.5–25 mcg/day q 1–2 wk intervals; usual maintenance dose is 25–50 mcg/day. Myxedema—2.5–5 mcg once daily initially; ↑ by 5–10 mcg/day q 1–2 wk up to 25 mcg/day, then ↑ by 12.5–25 mcg/day; usual maintenance dose is 25–50 mcg/day. Simple goiter—5 mcg once daily initially; ↑ by 5–10 mcg/day q 1–2 wk up to 25 mcg/day, then ↑ by 12.5–25 mcg/day q wk until desired effect is obtained; usual maintenance dose is 50–100 mcg/day. T3 suppression test—75–100 mcg daily for 7 days. Radioactive 131I is administered before and after 7-day course.
Oral (Geriatric Patients or Patients with Cardiovascular Disease) 5 mcg /day initially; ↑ by no more than 5 mcg/day q 2 wk.
Intravenous (Adults) Myxedema coma—25–50 mcg initially (if cardiovascular disease is present, initial dose should be 10–20 mcg). Additional doses may be given, to a total of at least 65 mcg/day (not to exceed 100 mcg/day). Doses should be at least 4 hr but not more than 12 hr apart.

Availability (generic available)

Tablets: 5 mcg, 25 mcg, 50 mcg
Injection: 10 mcg/mL

Nursing implications

Nursing assessment

  • Assess apical pulse and BP prior to and periodically during therapy. Assess for tachyarrhythmias and chest pain.
  • Children: Monitor height, weight, and psychomotor development.
  • Lab Test Considerations: Monitor thyroid function studies prior to and during therapy.
    • Monitor blood and urine glucose in diabetic patients. Insulin or oral hypoglycemic dose may need to be increased.
  • Overdose is manifested as hyperthyroidism (tachycardia, chest pain, nervousness, insomnia, diaphoresis, tremors, weight loss). Usual treatment is to withhold dose for 2–6 days. Acute overdose is treated by induction of emesis or gastric lavage, followed by activated charcoal. Sympathetic overstimulation may be controlled by antiadrenergic drugs (beta blockers), such as propranolol. Oxygen and supportive measures to control symptoms are also used.

Potential Nursing Diagnoses

Deficient knowledge, related to medication regimen (Patient/Family Teaching)

Implementation

  • Oral: Administer as a single dose, preferably before breakfast to prevent insomnia.
    • Initial dose is low, especially in geriatric and cardiac patients. Dose is increased gradually, based on thyroid function tests. Side effects occur more rapidly with liothyronine because of its rapid onset of effect.
    • For patients with difficulty swallowing, tablets can be crushed and placed in 5–10 mL of water and administered immediately via dropper or spoon; do not store suspension.
  • Intravenous Administration
  • pH: No Data.
  • Intravenous: Liothyronine injection is for IV use only. Do not give IM or subcut. Administer doses at least 4 hr and not more than 12 hr apart. Base doses on continuous monitoring of patient and response to therapy.
    • Resume PO therapy as soon as patient is stable and able to take PO medication. When switching to PO therapy, discontinue IV liothyronine and initiate PO at low dose, increasing gradually according to patient’s response.
  • May be administered undiluted.
  • Rate: Administer as a bolus.

Patient/Family Teaching

  • Instruct patient to take medication as directed at the same time each day. Take missed doses as soon as remembered unless almost time for next dose. If more than 2–3 doses are missed, notify health care professional. Do not discontinue without consulting health care professional.
    • Explain to patient that medication does not cure hypothyroidism; it provides a thyroid hormone supplement. Therapy is lifelong.
    • Advise patient to notify health care professional if headache, nervousness, diarrhea, excessive sweating, heat intolerance, chest pain, increased pulse rate, palpitations, weight loss >2 lb/wk, or any unusual symptoms occur.
    • Caution patient to avoid taking other medications concurrently with thyroid preparations unless instructed by health care professional.
    • Instruct patient to inform health care professionals of thyroid therapy.
    • Emphasize importance of follow-up exams to monitor effectiveness of therapy. Thyroid function tests are performed at least yearly.
  • Pediatric: Discuss with parents the need for routine follow-up studies to ensure correct development. Inform patient that partial hair loss may be experienced by children on thyroid therapy. This is usually temporary.

Evaluation/Desired Outcomes

  • Resolution of symptoms of hypothyroidism and normalization of hormone levels.
References in periodicals archive ?
That prompted the state Board of Registration in Pharmacy to order Royal Palm to immediately stop the compounding and preparation of liothyronine sodium.
Liothyronine (Cytomel) produces fluctuating levels of T3, has a shorter elimination half-life than T4, and often requires twice-daily dosing.
(30) The subjects ate treated with Liothyronine compounded in a hydrophilic matrix system, employing hydroxypropyl-methylcellulose (HPMC) designed to be taken every 12 hours.
announced the planned presentation of non-clinical data on the use of its ProNeura subdermal implant for the long-term, sustained delivery of liothyronine (L-T3) during a poster session on Oct.
wonder these household were for in the place Littlewood LIOTHYRONINE Liothyronine is a thyroid hormone used to treat certain thyroid conditions including hypothyroidism.
Currently, Sigmapharm's product line consists of Adefovir Dipivoxil Tablets, for hepatitis B, which is the first and only generic product equivalent to Hepsera tablets; Sodium Phenylbutyrate Powder, for urea cycle disorders, which is equivalent to Buphenyl powder; Acitretin Capsules, which is equivalent to Soriatane capsules, with a primary indication for the treatment of severe psoriasis; and Liothyronine Sodium Tablets, for hypothyroidism, which is the most stable Liothyronine product on the market, with a recently Food and Drug Administration-approved shelf life of five years.
Annual spend - PS19,295,030 | Liothyronine - is a thyroid hormone used to treat certain thyroid conditions.
B also should be presented non-ketamine alternatives, such as other adjunctive strategies (liothyronine, buspirone, cognitive-behavioral therapy) or a trial of nortriptyline or a monoamine oxidase inhibitor.
Michelle and Denise point out that many doctors are unaware of new blood tests and other treatment options, such as natural desiccated thyroid, synthetic combination hormone replacement and Liothyronine (T3 only).
ESTES PARK, COLO.--Adding liothyronine is a reasonable treatment strategy when symptoms of hypothyroidism persist on optimal levothyroxine alone, according to Dr.
Combination levothyroxine / liothyronine (LT4/LT3) therapy is supported by a biologically plausible mechanism of benefit in symptomatic patients who are biochemically euthyroid on LT4.
The thyroid is a butterfly-shaped endocrine gland located at the throat that produces numerous related hormones: thyroxin (also known as T4), liothyronine (also known as T3), T2, and T1.